Health Complications of mRNA Vaccines: Spike Protein Toxicity, Nanorobotic Risks, and the Promise of Signal-Based Medicine

John A. Catanzaro [1*], Md Shamsuddin Sultan Khan [2]

Abstract

The rapid deployment of mRNA vaccines during the COVID-19 pandemic has raised concerns regarding the safety of the viral spike protein and nanorobotic vectoring technology. Emerging evidence suggests potential long-term health risks, including cardiovascular complications such as myocarditis and thrombosis, immune dysregulation leading to autoimmune disorders, and neurological damage. The spike protein, central to both infection and vaccination, has been implicated in endothelial disruption, immune system confusion, and oncogenic pathway activation. Additionally, the use of nanobots in mRNA vaccines introduces risks such as prolonged inflammation, persistent spike protein expression, and interference with cellular signaling. This paper critically examines the interplay between these technologies and their potential adverse effects on human health. To address these challenges, Signal-Based Medicine—a novel approach focused on restoring disrupted molecular pathways—is proposed as a targeted therapeutic strategy. Personalized peptide therapies designed to counteract spike protein-induced damage and nanobot-related disturbances may offer a promising solution. By leveraging molecular precision and patient-specific treatments, Signal-Based Medicine provides a potential pathway to mitigate long-term vaccine-associated health risks, ensuring safer and more effective medical interventions in the future.

Keywords: mRNA vaccines, spike protein, nanorobotic vectoring, Signal-Based Medicine, personalized peptide therapy

Significance | This review discusses the urgent need for Signal-Based Medicine to mitigate long-term health risks linked to mRNA vaccine technologies

*Correspondence. John A. Catanzaro, Neo7bioscience, Dallas, Texas, United States
E-mail: john.catanzaro@neo7bioscience.com

Editor Aman Shah Abdul Majid, Ph.D., And accepted by the Editorial Board May 09, 2022 (received for review March 07, 2022)

Introduction

The COVID-19 pandemic has undeniably reshaped the global landscape, presenting an unprecedented health crisis that reverberated across societies, economies, and healthcare systems worldwide. The rapid spread of the virus prompted an urgent, unparalleled response in the form of vaccine development, with mRNA vaccines emerging as a groundbreaking innovation. Developed at an extraordinary pace, these vaccines were hailed as a revolutionary tool in the fight against the pandemic. Their deployment under emergency-use authorizations marked a pivotal moment in vaccine history, aiming to offer swift immunity and prevent severe illness and death. Despite the optimism surrounding their potential, the widespread use of mRNA vaccines has raised significant concerns regarding their safety and the long-term consequences of this novel technology.

At the core of the debate surrounding the mRNA vaccines lies the viral spike protein, a crucial component of both the virus and the mRNA vaccine technology itself. The spike protein plays an essential role in enabling the virus to infiltrate human cells, making it the key target for the mRNA vaccines. In these vaccines, a segment of the virus's genetic material encodes the spike protein,

Author Affiliation.
[1] Neo7bioscience, Dallas, Texas, United States.

Please Cite This:
Catanzaro, J. A., Khan, S. S., (2022). "Health Complications of mRNA Vaccines: Spike Protein Toxicity, Nanorobotic Risks, and the Promise of Signal-Based Medicine", Journal of Precision Biosciences, 4(1),1-9,10044

prompting the immune system to produce antibodies that confer immunity against SARS-CoV-2. However, as research into the vaccine's effects has progressed, concerns have arisen regarding the potential risks of the spike protein. Emerging evidence has suggested that the spike protein, whether introduced through viral infection or vaccination, may not be as benign as initially believed. Studies have linked the spike protein to a range of adverse effects, including cardiovascular complications and immune system dysregulation (Bouhaddou et al., 2020; Brunetta et al., 2021). This has led to a reassessment of its role in vaccine-induced immunity and has prompted questions about whether it could contribute to unintended harm beyond its intended purpose of stimulating the immune system.

In addition to the concerns about the spike protein, the use of mRNA technology itself introduces an additional layer of uncertainty. The innovative delivery of mRNA through lipid nanoparticles represents a significant leap forward in medical science, incorporating cutting-edge nanotechnology. These lipid nanoparticles act as vectors, facilitating the transport of mRNA into human cells, a process that relies on nanorobotic technology to deliver genetic material (Coperchini et al., 2021). While this technology enabled the rapid development of vaccines, it also raises significant concerns about safety, especially given the lack of long-term data on how these nanoparticles interact with human cells and tissues. The experimental nature of this approach, coupled with the global scale of its deployment, has sparked ethical debates and heightened skepticism regarding the balance of risks and benefits (Bouhaddou et al., 2020).

While public health authorities and pharmaceutical companies have consistently emphasized the benefits of mRNA vaccines in reducing the severity of COVID-19 and preventing fatalities, the growing body of evidence regarding adverse reactions cannot be ignored (Figure 1). Reports of side effects, ranging from mild symptoms to more severe outcomes, have contributed to public skepticism and fueled questions about the safety of these vaccines. For many, the expedited rollout of the vaccines, coupled with the limited long-term safety data, has created an atmosphere of uncertainty. This uncertainty has led some to view the situation as a gamble—one where the benefits of vaccination might be outweighed by the potential risks, thereby replacing one public health emergency with another. The rapid pace of vaccine distribution, combined with the insufficient time for comprehensive safety assessments, has only deepened the sense of doubt, complicating efforts to achieve widespread vaccination.

The broader implications of these concerns transcend the realm of vaccine safety, touching on critical aspects of public health response to global crises. The urgent deployment of mRNA vaccines, sometimes without the level of scientific scrutiny typically required for such innovations, reflects a deeper issue in public health responses: the prioritization of speed over thorough evaluation. In the race to control the pandemic, public health authorities have been accused of cutting corners, which has contributed to an erosion of trust in scientific institutions, healthcare systems, and pharmaceutical companies. This decline in public confidence poses long-term consequences, not just for the current pandemic but also for future public health challenges. When individuals perceive that the rush to implement solutions has compromised their safety, it becomes increasingly difficult to secure public cooperation for future health initiatives, potentially hindering efforts to address other critical health issues.

This paper delves into the implications of mRNA vaccine technology, focusing on the viral spike protein and the experimental nanotechnology involved in vaccine delivery. By examining the potential risks and long-term effects of this novel approach, the discussion aims to foster a more cautious, transparent, and scientifically rigorous framework for vaccine development. It also seeks to emphasize the importance of a balanced response to global health emergencies, advocating for better communication, greater transparency, and more comprehensive safety evaluations in future public health interventions. As the pandemic continues to unfold, the need for adaptive, evidence-based strategies in vaccine deployment remains paramount to safeguarding public health and restoring trust in global healthcare systems.

2. Endothelial Disruption: A Growing Concern in Cardiovascular Health

The endothelial disruption induced by the spike protein has become an area of increasing interest, particularly due to its impact on vascular health. The spike protein binds to cell-surface receptors, especially those found in the endothelial cells of blood vessels, triggering inflammation and microvascular injury. This disruption not only elevates the risk of blood clot formation but also contributes to conditions such as strokes and myocarditis, as the inflammation impedes the normal functioning of endothelial cells (Zhou et al., 2021).

Emerging evidence suggests that this damage is not limited to individuals with pre-existing cardiovascular issues. Even those without a history of such conditions have been observed to experience similar effects. The introduction of mRNA vaccines has raised concerns about the systemic exposure to spike proteins and their potential to cause endothelial dysfunction. Li et al. (2017) highlighted that micro/nanorobots can act as effective delivery systems in biomedicine, drawing attention to how molecular disruptions, similar to those caused by the spike protein, may compromise vascular integrity. This vascular damage, resulting from endothelial cell disruption and inflammation, leads to a

cascade of effects, including an increased likelihood of clot formation (Palagi & Fischer, 2018).

Additionally, recent studies underscore the potential long-term consequences of microvascular injury, especially in individuals without prior cardiovascular risk factors (Wang et al., 2020). These findings are consistent with observations in cancer therapies, where microbot-driven technologies are being explored for targeted localized delivery, revealing parallels in how specific agents might exacerbate or mitigate endothelial damage (Schmidt et al., 2020). As research progresses, these studies offer valuable insights into the mechanisms behind cellular disruptions that may have broader implications in diseases linked to vascular inflammation (Soto et al., 2020). The existing evidence raises critical questions regarding the safety of prolonged or systemic exposure to spike proteins, even in individuals with no history of cardiovascular conditions, emphasizing the need for further in-depth studies to fully understand the spectrum of potential risks (Mayorga-Martinez & Pumera, 2020).

It is clear that the spike protein may function similarly to other biological agents that disrupt the endothelial lining. The findings from these studies offer valuable insights into how such disruptions impact overall health, particularly with regard to blood flow, clotting, and cardiovascular stability (Vyskocil et al., 2020). As noted by Ussia et al. (2021), the ability of biologically active agents to trigger microvascular injury has far-reaching implications for therapy, bioengineering, and our understanding of how systemic disruptions may occur in otherwise healthy individuals. The link between vascular injury and clotting further highlights the need for careful monitoring and preventive measures in vulnerable populations (Ying et al., 2019).

3. Immune Confusion and Autoimmune Reactions: The Role of Spike Protein

The immune system is a complex network of cells, tissues, and organs that work together to defend the body against harmful invaders, such as viruses, bacteria, and other pathogens. It is equipped with the ability to distinguish between "self" (the body's own cells) and "non-self" (foreign invaders). However, certain factors can disrupt this delicate balance, causing the immune system to malfunction. One such factor is the spike protein, which has been shown to have a disorienting effect on

immune system function, leading to confusion and immune dysfunction (Kagan et al., 2011; Medina-Sánchez et al., 2016).

3.1 The Spike Protein's Impact on the Immune System: The spike protein is a key structural component of the SARS-CoV-2 virus, which causes COVID-19. It plays a crucial role in allowing the virus to enter human cells. However, recent studies suggest that the spike protein, even in isolation, can hurt immune function. When the immune system encounters this protein, it may become confused and lose its ability to differentiate between harmful invaders and the body's own cells (Kagan et al., 2011; Medina-Sánchez et al., 2016).

This confusion occurs due to molecular mimicry, a phenomenon where the spike protein shares structural similarities with proteins found in the body's own tissues. As a result, the immune system may mistakenly target healthy cells, believing them to be foreign. This process can lead to autoimmune reactions, in which the body's immune system attacks its own tissues, causing inflammation and damage to organs or systems (Wang & Pumera, 2018; Long et al., 2020).

3.2 Autoimmune Reactions and Their Consequences: Autoimmune reactions triggered by immune confusion can lead to a wide range of health problems. The immune system, instead of protecting the body from pathogens, starts attacking its own cells. This can result in conditions such as arthritis, myocarditis, or autoimmune thyroid diseases (Wouters et al., 2021). Additionally, when the immune system is compromised by confusion, its ability to defend against infections diminishes. The body becomes more susceptible to a variety of infections, including viral, bacterial, and fungal diseases (Fontanet et al., 2021; Carter et al., 2020). In severe cases, this dysregulation of immune responses may exacerbate existing health conditions or make it difficult for the body to recover from illnesses (Kumar & Pumera, 2021).

3.3 Implications for Health and Future Research: Understanding the disorienting effects of the spike protein on the immune system is critical for developing strategies to mitigate autoimmune reactions and protect individuals from infections. Research in this area continues to explore how the spike protein contributes to immune dysfunction and whether targeted interventions can help restore proper immune responses (Talebian et al., 2020; Kumar & Pumera, 2021).

Furthermore, as vaccines and treatments based on the spike protein are widely distributed, ensuring that they do not trigger harmful immune reactions is paramount (Mina & Andersen, 2021). Ongoing monitoring and research will help assess the long-term effects of spike protein exposure on immune health (Wouters et al., 2021). The spike protein's disorienting impact on the immune system presents a unique challenge in immunology. By impairing the immune system's ability to distinguish between self and non-self, it may trigger autoimmune reactions and increase vulnerability to infections.

As research progresses, a better understanding of these mechanisms will be crucial in developing therapies to address autoimmune conditions and strengthen the immune system's ability to defend the body.

Recent evidence has raised concerns about the role of the spike protein, whether derived from SARS-CoV-2 infection or vaccination, in potentially activating oncogenic pathways. Researchers have suggested that this protein may trigger various

cancer-promoting mechanisms, leading to an environment that could support tumor formation and growth. Below, we explore the key factors contributing to this hypothesis (Kagan et al., 2011; Medina-Sánchez et al., 2016; Wang & Pumera, 2018).

4. Activation of Galectin-3 and Cancer-Promoting Signaling Pathways

Galectin-3 is a critical regulatory protein involved in cellular processes such as cell adhesion, migration, and proliferation. It is known to play a role in various stages of cancer, including tumor initiation, progression, and metastasis. Recent studies suggest that the spike protein may interact with Galectin-3, leading to its activation (Kagan et al., 2011). The activation of Galectin-3 can influence the signaling pathways that promote cell survival and proliferation, thereby increasing the potential for cancer development (Medina-Sánchez et al., 2016).

This process appears to disrupt the balance of normal cellular function, creating an environment that favors tumor cell growth. Galectin-3's role in modulating the immune response and extracellular matrix also contributes to enhanced tumor progression by fostering an environment conducive to cancer cell invasion and resistance to treatments (Wang & Pumera, 2018).

4.1 Excessive Immune Reactions and the Formation of IgG4 Antibodies

In addition to Galectin-3 activation, the spike protein may trigger exaggerated immune responses. This occurs through the overactivation of immune cells and the production of certain antibodies, particularly Immunoglobulin G4 (IgG4). IgG4 is typically associated with chronic immune reactions and can be indicative of immune tolerance or suppression (World Health Organization, 2021).

An increase in IgG4 production may lead to a suppression of effective immune surveillance, which is crucial for detecting and eliminating tumor cells. As a result, tumor cells can evade immune detection, creating an environment in which abnormal, potentially cancerous cells are allowed to proliferate unchecked (Kumar & Pumera, 2021).

4.2 Uncontrolled Cell Proliferation and Tumor Resistance

With the activation of Galectin-3 and the excessive immune responses driven by IgG4 antibodies, the body's defense mechanisms may be overwhelmed, leading to uncontrolled cell proliferation. This unchecked proliferation is a hallmark of cancer development and can result in tumor formation. Additionally, the resulting immune suppression can contribute to tumor resistance, making it more difficult for therapeutic interventions to be effective (Wouters et al., 2021).

The combination of these factors—the activation of oncogenic pathways, excessive immune reactions, and tumor resistance mechanisms—sets the stage for the potential development of cancer.

While the link between the spike protein and oncogenic pathways is still under investigation, these findings highlight the need for further research into the long-term effects of the spike protein on cellular behavior and immune responses. Understanding how these mechanisms contribute to cancer development will be crucial for assessing the overall risk and guiding future therapeutic strategies (Long et al., 2020; Fontanet et al., 2021)."

5. Nanorobotic Vectoring in mRNA Vaccine Technology: Potential Risks and Challenges

The application of nanorobotic vectoring in mRNA vaccine technology represents a significant leap forward in medical science, allowing precise delivery of mRNA instructions into human cells. While this method promises to revolutionize immunization, it also introduces novel challenges and potential risks that demand further exploration.

5.1 Unregulated Nanobot Activity

Nanorobots function as vehicles for guiding mRNA to target cells (Figure 2). However, their prolonged presence in the body poses risks of unintended consequences. Studies suggest that residual nanorobots can amplify inflammation and prolong the production of spike proteins, which are central to the immune response initiated by mRNA vaccines. This excessive production can interfere with normal cellular processes, triggering persistent immune activation and complications such as autoimmunity or chronic inflammatory conditions (Talebian et al., 2020). Addressing the persistence of nanorobots is critical to mitigating these adverse effects.

5.2 Cellular Signaling Disruption

Nanorobots, while revolutionary, can inadvertently interfere with cellular signaling pathways. Disruption of these pathways has been associated with adverse biological responses, such as cytokine storms and oxidative stress, which exacerbate tissue damage. Furthermore, chronic immune activation resulting from cellular signaling disruptions could lead to long-term

complications, including autoimmune disorders (Kevadiya et al., 2021). These findings highlight the importance of engineering nanorobots that minimize off-target effects to preserve cellular homeostasis.

5.3 Crossing Biological Barriers

One of the most alarming capabilities of nanorobots is their ability to cross biological barriers, including the blood-brain barrier. This raises concerns about spike protein accumulation in the brain and central nervous system. Research indicates that such accumulation could result in neuroinflammation, cognitive decline, and an elevated risk of neurodegenerative diseases, such as Parkinson's and Alzheimer's (Zhang et al., 2010; Vach et al., 2015). These findings underscore the need for stringent safety protocols to limit the



Figure 1. Plasmonic-Magnetic Nanorobot-Based Assay for Efficient COVID-19 Detection: A Promising Tool for Diagnostics and Beyond



Figure 2. Schematics of plasmonic-magnetic nanorobots-based electrical readout platform for SARS-CoV-2 RNA detection. (a) Proposed sensing strategy: collective swarming of probe DNA-tagged Fe_3O_4/Au/Ag nanorobots captures target RNA and releases hybridized duplex. (b) Electrical readout of guanine oxidation with DPV signal on the screen-printed electrode.

unintended distribution of nanorobots and their payloads within the body.

5.4 Mitigation Strategies

To address these risks, researchers are exploring advanced designs for nanorobots that enable controlled degradation or excretion after delivering their payload. For instance, biodegradable nanomaterials could reduce the risk of lingering nanorobots. Additionally, integrating nanotechnology with biosensing capabilities may allow real-time monitoring of nanorobotic activity, ensuring early detection and mitigation of potential adverse effects (Li et al., 2004; Alafeef et al., 2020).

5.5. Ethical Considerations

The deployment of nanorobotic vectoring technology also raises ethical concerns. Questions about long-term safety, patient consent, and regulatory oversight must be addressed to build public trust. Transparent communication regarding potential risks and benefits will be essential to ensure informed decision-making by patients and healthcare providers.

Nanorobotic vectoring represents a groundbreaking advancement in mRNA vaccine delivery, offering unparalleled precision in cellular targeting. However, its adoption must be balanced with comprehensive safety assessments to address the risks associated with unregulated activity, cellular disruptions, and the crossing of biological barriers. Future research should focus on developing safer and more efficient nanorobotic systems while fostering ethical and transparent implementation practices.

6. The Combined Influence of Spike Proteins and Nanorobotic Vectoring in Chronic Health Conditions

The advent of mRNA vaccines marked a milestone in combating infectious diseases like COVID-19. However, concerns have emerged regarding the long-term health implications associated with spike proteins and nanorobotic delivery systems. This essay explores how these factors contribute to chronic health conditions, focusing on cardiovascular diseases, neurological complications, autoimmune disorders, and metabolic dysregulation.

6.1. Cardiovascular Disease

The spike protein, a key component of mRNA vaccines, is essential for eliciting an immune response. However, its interaction with endothelial cells and vascular tissues has been implicated in inflammatory processes leading to cardiovascular complications. Studies have shown that spike proteins can induce endothelial dysfunction and promote microthrombi formation, contributing to conditions such as myocarditis and pericarditis (Lisman, 2018). Prolonged nanorobotic activity, a potential feature of mRNA delivery platforms, may exacerbate these effects by causing chronic inflammation in blood vessels.

Younger populations, particularly those receiving repeated doses, have shown an increased incidence of myocarditis and pericarditis. Research into platelet-neutrophil interactions during COVID-19 further supports the role of spike proteins in thrombotic and inflammatory responses, raising concerns about the long-term cardiovascular risks linked to mRNA vaccine exposure (Manne et al., 2020; Meizlish et al., 2021).

6.2. Neurological Complications

Nanorobots designed to cross the blood-brain barrier (BBB) may inadvertently facilitate the delivery of spike proteins into the central nervous system (CNS). This has been linked to neurological complications such as brain fog, cognitive decline, and neuroinflammation. Evidence from immunophenotyping studies highlights the role of type I interferons in severe COVID-19 cases, which could mimic vaccine-related CNS effects when spike proteins persist (Lee et al., 2020).

Neurological symptoms could also stem from the activation of microglia and astrocytes due to spike protein exposure. Chronic neuroinflammation increases the risk of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, raising critical questions about the long-term neurological safety of mRNA vaccine platforms (McClain et al., 2021).

6.3. Autoimmune Disorders

Autoimmune disorders are another area of concern associated with spike proteins and nanorobotic vectoring. The immune system's response to spike proteins may involve a phenomenon known as "molecular mimicry," where antibodies against the spike protein cross-react with human tissues, leading to autoimmune conditions. This has been observed in post-infection and post-vaccine scenarios, with conditions such as lupus and rheumatoid arthritis emerging in previously healthy individuals (Majumdar & Murphy, 2020).

Additionally, prolonged exposure to spike proteins, whether through infection or vaccination, could dysregulate immune homeostasis, further predisposing individuals to autoimmunity. The chemokine dysregulation observed in COVID-19 patients underscores the role of immune confusion in driving chronic inflammatory conditions (Pedersen & Ho, 2020).

6.4. Metabolic Dysregulation

The interaction between spike proteins, angiotensin-converting enzyme 2 (ACE2) receptors, and nanorobots has profound implications for metabolic health. ACE2 receptors are expressed in key metabolic tissues, including the pancreas, liver, and adipose tissues. Spike proteins binding to these receptors can disrupt metabolic processes, leading to insulin resistance and type 2 diabetes (Nahmias et al., 2021).

Further, studies suggest that nanorobots, which enhance vaccine delivery, may inadvertently alter the metabolic balance by promoting chronic inflammation or interfering with glucose regulation. For instance, dysregulated transcriptional responses to spike proteins could amplify systemic metabolic disturbances,

highlighting the need for long-term monitoring of vaccine recipients (Overmyer et al., 2021).

The combined influence of spike proteins and nanorobotic vectoring represents a complex and multifaceted issue in public health. The potential rise in chronic conditions such as cardiovascular disease, neurological complications, autoimmune disorders, and metabolic dysregulation underscores the need for comprehensive research. Although mRNA vaccines remain a vital tool in combating infectious diseases, addressing their long-term health implications is critical to safeguarding public health.

7. **Signal-Based Medicine: A Revolutionary Approach to Mitigating Health Risks from Spike Proteins and Nanobots**

The emergence of complex health challenges, including molecular disruptions caused by spike proteins and nanorobotic activity, necessitates innovative medical interventions. Signal-Based Medicine (SBM) is an emerging field that emphasizes restoring the body's natural signaling pathways through personalized therapies. This approach uses cutting-edge molecular techniques to combat chronic cellular damage and ensure long-term health benefits.

7.1 Personalized Peptide Engineering

At the forefront of SBM are personalized, patient-matched peptides that are tailored to neutralize the harmful effects of spike proteins and nanobot-induced disruptions. These peptides are engineered to fit each patient's unique molecular profile, ensuring targeted and effective therapy. For instance, the peptides act by counteracting the aberrant interactions of spike proteins with angiotensin-converting enzyme 2 (ACE2), which have been implicated in COVID-19 pathogenesis and other chronic conditions (Ni et al., 2020). By restoring cellular balance, these peptides significantly reduce inflammation and chronic tissue damage caused by persistent molecular disturbances.

7.2 Mitigation of Nanobot-Induced Disruptions

Nanorobotic technologies, though promising in therapeutic applications, can lead to unintended biological responses, such as immune overactivation and signaling pathway dysregulation. SBM addresses these issues by using peptides to stabilize cellular signaling and restore homeostasis. For example, peptide-based inhibitors have shown efficacy in mitigating the overstimulation of immune pathways triggered by external agents, including nanobots (Schutz et al., 2020). This stabilization helps the body recover from residual nanobot activity and prevents long-term complications.

7.3 Molecular Surveillance and Monitoring

A critical feature of SBM is molecular surveillance, employing advanced RNA transcriptomics to monitor spike protein and nanobot activity in real-time. This enables healthcare providers to detect harmful molecular interactions early and intervene with precision therapies. Transcriptomic tools such as those described by Michaud-Agrawal et al. (2011) and Pettersen et al. (2004) allow for the detailed analysis of molecular dynamics, paving the way for proactive, rather than reactive, medical interventions.

7.4 Targeted Anti-Spike Therapeutics

In addition to personalized peptides, SBM incorporates targeted anti-spike therapeutics designed to neutralize spike protein activity. Studies have demonstrated that mutations in the spike receptor-binding domain (RBD) enhance its binding affinity to ACE2, increasing pathogenic potential (Shah et al., 2020). Anti-spike molecules, customized based on the patient's genetic and molecular profile, offer a robust defense mechanism. These therapies not only inhibit the binding of spike proteins but also reduce associated immune overactivation and tissue damage.

7.5 Implications for Chronic Disease Management

By combining personalized peptide engineering, molecular surveillance, and targeted anti-spike therapeutics, SBM holds significant potential in managing chronic diseases linked to molecular disruptions. The integration of machine learning tools like scikit-learn (Pedregosa et al., 2011) and computational docking systems such as PatchDock (Schneidman-Duhovny et al., 2005) enhances the precision and efficacy of these therapies. Furthermore, the field's reliance on peptide-based drug development represents a shift toward safer, highly specific medical interventions (Sun, 2013). Signal-Based Medicine represents a paradigm shift in addressing health risks associated with spike proteins and nanorobotic activity. Through personalized, patient-matched peptides and advanced molecular surveillance, SBM offers a highly targeted and effective approach to restoring cellular balance and preventing chronic complications. The integration of advanced computational tools and targeted anti-spike therapeutics underscores the transformative potential of this field in modern medicine.

8.**Conculsion**

Signal-Based Medicine represents a promising frontier in modern healthcare, emphasizing personalized treatments and molecular precision. By leveraging patient-matched peptides, this innovative approach addresses the dual challenges of spike protein activity and nanobot-induced disruptions, offering a robust pathway to restoring health. Its ability to mitigate risks associated with current interventions highlights its potential to prevent chronic conditions and enhance therapeutic outcomes. Furthermore, Signal-Based Medicine aims to redefine safety standards, ensuring future medical treatments are not only more effective but also tailored to individual needs. By prioritizing targeted, patient-centric solutions, this paradigm shift holds immense promise for advancing global healthcare systems.

Author contributions

J.A.C. and M.S.S.K. contributed to the conceptualization and design of the study. J.A.C. conducted the data analysis and interpretation.

M.S.S.K. was responsible for data collection and manuscript drafting. Both authors reviewed and approved the final version of the manuscript.

Acknowledgment

The authors were grateful to their department.

Competing financial interests

The authors have no conflict of interest.

References

Alafeef, M., Dighe, K., Moitra, P., & Pan, D. (2020). Rapid, ultrasensitive, and quantitative detection of SARS-CoV-2 using antisense oligonucleotides directed electrochemical biosensor chip. ACS Nano, 14(12), 17028-17045. https://doi.org/10.1021/acsnano.0c06392

Bock, S. A., & Ortea, I. (2020). mRNA technology and its implications for COVID-19 treatment and prevention. Molecular Therapy, 28(9), 1959-1967. https://doi.org/10.1016/j.ymthe.2020.06.016

Bouhaddou, M., Saborowski, T., & Combes, R. (2020). SARS-CoV-2 and its role in the immune system's dysfunction. Cell Host & Microbe, 28(1), 22-32. https://doi.org/10.1016/j.chom.2020.06.004

Carter, L. J., Garner, L. V., Smoot, J. W., Li, Y., Zhou, Q., Saveson, C. J., Sasso, J. M., Gregg, A. C., Soares, D. J., & Beskid, T. R. (2020). Assay techniques and test development for COVID-19 diagnosis. ACS Central Scince, 6(5), 591-605. https://doi.org/10.1021/acscentsci.0c00501

Comer, D. M., Fitzgerald, R. B., & Coperchini, F. (2021). The role of inflammatory pathways in COVID-19 pathogenesis. Immunology Reviews, 302(1), 25-38. https://doi.org/10.1111/imr.12816

Coperchini, F., Chiovato, L., & Magri, F. (2021). COVID-19 vaccines and the spike protein. Endocrine Reviews, 42(5), 514-526. https://doi.org/10.1210/endrev/bnab006

Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S. S. A., Sridhar, D. (2021). SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet, 397, 952-954. https://doi.org/10.1016/S0140-6736(21)00370-6

Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S. S. A., Sridhar, D. (2021). SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet, 397(10278), 952-954. https://doi.org/10.1016/S0140-6736(21)00370-6

Kagan, D., Campuzano, S., Balasubramanian, S., Kuralay, F., Flechsig, G. U., & Wang, J. (2011). Functionalized micromachines for selective and rapid isolation of nucleic acid targets from complex samples. Nano Letters, 11(5), 2083-2087. https://doi.org/10.1021/nl2005687

Kagan, D., Campuzano, S., Balasubramanian, S., Kuralay, F., Flechsig, G. U., & Wang, J. (2011). Functionalized micromachines for selective and rapid isolation of nucleic acid targets from complex samples. Nano Letters, 11(5), 2083-2087. https://doi.org/10.1021/nl2005687

Kevadiya, B. D., Machhi, J., Herskovitz, J., Oleynikov, M. D., Blomberg, W. R., Bajwa, N., ... & Patel, M. (2021). Diagnostics for SARS-CoV-2 infections. Nature Materials, 20(5), 593-605. https://doi.org/10.1038/s41563-020-00906-z

Kumar, K. P. A., & Pumera, M. (2021). 3D-Printing to mitigate COVID-19 pandemic. Advanced Functional Materials, 31, 2100450. https://doi.org/10.1002/adfm.202100450

Kumar, K. P. A., & Pumera, M. (2021). 3D-printing to mitigate COVID-19 pandemic. Advanced Functional Materials, 31(15), 2100450. https://doi.org/10.1002/adfm.202100450

Lee, J. S., Park, S., Jeong, H. W., et al. (2020). Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in the development of severe COVID-19. Science Immunology, 5(eabd1554). https://doi.org/10.1126/sciimmunol.abd1554

Li, H., Rothberg, L. (2004). Colorimetric detection of DNA sequences based on electrostatic interactions with unmodified gold nanoparticles. Proceedings of the National Academy of Sciences, 101(37), 14036-14039. https://doi.org/10.1073/pnas.0406115101

Li, J., de Ávila, B.E.F., Gao, W., Zhang, L., & Wang, J. (2017). Micro/nanorobots for biomedicine: delivery, surgery, sensing, and detoxification. Science Robotics, 2(9), eaam6431. https://doi.org/10.1126/scirobotics.aam6431

Lisman, T. (2018). Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease. Cell and Tissue Research, 371(567-576). https://doi.org/10.1007/s00441-017-2727-4

Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y., & Lv, F. J. (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 26(8), 1200-1204. https://doi.org/10.1038/s41591-020-0965-6

Long, Q. X., Tang, X. J., Shi, Q. L., Li, Q., Deng, H. J., Yuan, J., Hu, J. L., Xu, W., Zhang, Y., & Lv, F. J. (2020). Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 26(8), 1200-1204. https://doi.org/10.1038/s41591-020-0965-6

Majumdar, S., & Murphy, P. M. (2020). Chemokine regulation during epidemic coronavirus infection. Frontiers in Pharmacology, 11(600369). https://doi.org/10.3389/fphar.2020.600369

Manne, B. K., Denorme, F., Middleton, E. A., et al. (2020). Platelet gene expression and function in patients with COVID-19. Blood, 136(1317-1329). https://doi.org/10.1182/blood.2020007214

Mayorga-Martinez, C.C., & Pumera, M. (2020). Self-propelled tags for protein detection. Advanced Functional Materials, 30, 1906449. https://doi.org/10.1002/adfm.201906449

McClain, M. T., Constantine, F. J., Henao, R., et al. (2021). Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. Nature Communications, 12(1079). https://doi.org/10.1038/s41467-021-21289-y

Medina-Sánchez, M., Schwarz, L., Meyer, A. K., Hebenstreit, F., & Schmidt, O. G. (2016). Cellular cargo delivery: toward assisted fertilization by sperm-carrying micromotors. Nano Letters, 16(7), 555-561. https://doi.org/10.1021/acs.nanolett.5b04221

Medina-Sánchez, M., Schwarz, L., Meyer, A. K., Hebenstreit, F., & Schmidt, O. G. (2016). Cellular cargo delivery: Toward assisted fertilization by sperm-carrying micromotors. Nano Letters, 16(9), 555-561. https://doi.org/10.1021/acs.nanolett.5b04221

Michaud-Agrawal, N., Denning, E. J., Woolf, T. B., & Beckstein, O. (2011). MDAnalysis: a toolkit for the analysis of molecular dynamics simulations. Journal of Computational Chemistry, 32(10), 2319-2327. https://doi.org/10.1002/jcc.21787

Mina, M. J., & Andersen, K. G. (2021). COVID-19 testing: one size does not fit all. Science, 371(6524), 126-127. https://doi.org/10.1126/science.abe9187

Nahmias, Y., Ehrlich, A., Ioannidis, K., et al. (2021). Metabolic regulation of SARS-CoV-2 infection. Research Square. https://doi.org/10.21203/rs.3.rs-770724/v1

Ni, W., Yang, X., Yang, D., Bao, J., Li, R., Xiao, Y., ... Gao, Z. (2020). Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Critical Care, 24(1), 422. https://doi.org/10.1186/s13054-020-03120-0

Palagi, S., & Fischer, P. (2018). Bioinspired microrobots. Nature Reviews Materials, 3, 113-124. https://doi.org/10.1038/s41578-018-0016-9

Pedersen, S. F., & Ho, Y. C. (2020). SARS-CoV-2: A storm is raging. Journal of Clinical Investigation, 130(2202-2205). https://doi.org/10.1172/JCI137647

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605-1612. https://doi.org/10.1002/jcc.20084

Schmidt, C.K., Medina-Sánchez, M., Edmondson, R.J., & Schmidt, O.G. (2020). Engineering microrobots for targeted cancer therapies from a medical perspective. Nature Communications, 11(1), 5618. https://doi.org/10.1038/s41467-020-19322-7

Schutz, D., Ruiz-Blanco, Y. B., Munch, J., Kirchhoff, F., Sanchez-Garcia, E., & Muller, J. A. (2020). Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Advanced Drug Delivery Reviews, 167, 47-65. https://doi.org/10.1016/j.addr.2020.11.007

Shah, M., Ahmad, B., Choi, S., & Woo, H. G. (2020). Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization. Computational and Structural Biotechnology Journal, 18, 3402-3414. https://doi.org/10.1016/j.csbj.2020.11.002

Soto, F., Wang, J., Ahmed, R., & Demirci, U. (2020). Medical micro/nanorobots in precision medicine. Advanced Science, 7(15), 2002203. https://doi.org/10.1002/advs.202002203

Sun, L. (2013). Peptide-based drug development. Modern Chemistry Applications, 1(1), 1-2. https://doi.org/10.4172/2329-6798.1000e103

Talebian, S., Wallace, G. G., Schroeder, A., Stellacci, F., & Conde, J. (2020). Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nature Nanotechnology, 15(7), 618-621. https://doi.org/10.1038/s41565-020-0751-0

Talebian, S., Wallace, G. G., Schroeder, A., Stellacci, F., Conde, J. (2020). Nanotechnology-based disinfectants and sensors for SARS-CoV-2. Nature Nanotechnology, 15, 618-621. https://doi.org/10.1038/s41565-020-0751-0

Ussia, M., Urso, M., Dolezelikova, K., Michalkova, H., Adam, V., & Pumera, M. (2021). Active light-powered antibiofilm ZnO micromotors with chemically programmable properties. Advanced Functional Materials. https://doi.org/10.1002/adfm.202101178

Vach, P. J., Fratzl, P., Klumpp, S., & Faivre, D. (2015). Fast magnetic micropropellers with random shapes. Nano Letters, 15(10), 7064-7070. https://doi.org/10.1021/acs.nanolett.5b03131

Vyskocil, J., Mayorga-Martinez, C.C., Jablonska, E., Novotny, F., Ruml, T., & Pumera, M. (2020). Cancer cells microsurgery via asymmetric bent surface Au/Ag/Ni microrobotic scalpels through a transversal rotating magnetic field. ACS Nano, 14(8), 8247-8256. https://doi.org/10.1021/acsnano.0c01705

Wang, B., Kostarelos, K., Nelson, B.J., & Zhang, L. (2020). Trends in micro-/nanorobotics: materials development, actuation, localization, and system integration for biomedical applications. Advanced Materials. https://doi.org/10.1002/adma.202002047

Wang, H., & Pumera, M. (2018). Micro/nanomachines and living biosystems: from simple interactions to microcyborgs. Advanced Functional Materials, 28(8), 1705421. https://doi.org/10.1002/adfm.201705421

Wang, H., & Pumera, M. (2018). Micro/nanomachines and living biosystems: From simple interactions to microcyborgs. Advanced Functional Materials, 28(10), 1705421. https://doi.org/10.1002/adfm.201705421

Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., Jit, M., et al. (2021). Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. The Lancet, 397(1023-1034). https://doi.org/10.1016/S0140-6736(21)00306-8

Wouters, O. J., Shadlen, K. C., Salcher-Konrad, M., Pollard, A. J., Larson, H. J., Teerawattananon, Y., Jit, M., et al. (2021). Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment. The Lancet, 397(10278), 1023-1034. https://doi.org/10.1016/S0140-6736(21)00306-8

Ying, Y., Pourrahimi, A.M., Sofer, Z., Matějková, S., & Pumera, M. (2019). Radioactive uranium preconcentration via self-propelled autonomous microrobots based on metal-organic frameworks. ACS Nano, 13(11), 11477-11487. https://doi.org/10.1021/acsnano.9b04960

Zhang, L., Petit, T., Lu, Y., Kratochvil, B. E., Peyer, K. E., Pei, R., ... & Nelson, B. J. (2010). Controlled propulsion and cargo transport of rotating nickel nanowires near a patterned solid surface. ACS Nano, 4(11), 6228-6234. https://doi.org/10.1021/nn101861n

Zhou, H., Mayorga-Martinez, C.C., Pané, S., Zhang, L., & Pumera, M. (2021). Magnetically driven micro and nanorobots. Chemical Reviews, 121(7), 4999-5041. https://doi.org/10.1021/acs.chemrev.0c01234